Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

cure cystic fibrosis

BY LAUNCHING NEW THERAPEUTICS VENTURES IN PARTNERSHIP WITH

JOIN OUR EFFORTS TO

cure cystic fibrosis

BY LAUNCHING NEW THERAPEUTICS VENTURES IN PARTNERSHIP WITH
About DSV

Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin out and invest in science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures.

We operate in 4 sectors: Pharmaceuticals, Energy, Agriculture and Computation, tackling the challenges defining those areas by taking a first-principles approach and partnering with leading institutions.

 

The Challenge

Cystic Fibrosis (CF) is one of the most common genetic diseases that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span. The mutational profile across CF patients is complex and while life-extending therapies exist for the most common mutations, large patient populations remain uncatered for, and curative therapies are lacking.

One of the key challenges to overcome for curative approaches to CF is delivery. CF is a systemic disease with the most life-threatening symptoms occurring in the lung, which is why the respiratory delivery route has been the focus so far. However, to tackle all affected tissues, we will need a delivery strategy to reach all affected tissues whilst ensuring the therapeutic agent reaches the lung in sufficient concentrations.

 

OUR TAKE ON BUILDING NEW VENTURES IN THIS SPACE

We have teamed up with the Cystic Fibrosis Foundation (CFF), the world’s leading organisation with the mission to cure CF and to provide all people with CF the opportunity to lead long, fulfilling lives. Together we will focus on developing lifesaving new therapies for larger numbers of people with CF – including those with rare and nonsense mutations – and pursuing daring, new opportunities to one day develop a lifelong cure that targets the disease from every angle. You will be applying DSV’s approach to ideation and venture building whilst tapping into CFF’s network and expertise, including technical, non-clinical and regs throughout the process.

 

The Opportunity for you

Joining DSV is a fantastic opportunity to develop concepts for and launch your own therapeutics startup.

Taking up a Founding Analyst (FA) role at DSV differs quite significantly from the entrepreneur in residence (EIR) role in other funds or venture studios. Working with us and other founders at DSV, as well as our mentors, you’ll have access to a completely new kind of environment for creating science companies, one that does not start with university IP, but with a systematic rework of an opportunity area from first principles.

Instead of scouting for existing technologies that might overcome a specific challenge, an FA starts with identifying the areas where there is neglect or repeated failure yet potential solutions exist if considered from a different perspective, mapping the limitations to existing approaches at the specific and macro-level and considering the constraints of the broader ecosystem (capital, expertise, IP, knowledge, competition).

Within less than 12 months you will have developed a few promising concepts, built a team of multidisciplinary co-founders and experienced advisors, incorporated a new company and spun-out of DSV to start the early tech development / proof-of-concept work with investment secured from DSV and CFF.

 

Our offer

We provide a monthly salary (at a pre-seed stage startup level) to bridge the gap between developing your new venture and getting it to an investable company stage. CFF will bring deep expertise in the space, apply time from their own staff to assist with the venture development process and DSV will support you with building a founding team and securing investors. You and your Co-Founder(s) will own 80% of the new venture at inception and the pre-seed investment capital is already secured from CFF.

 

Our impact

We’ve so far built and invested in 9 brand new companies in the pharma in the curative therapeutics sector including in neurodegeneration, oncology and infectious diseases.

You can read some our Founder stories here.

 

Who should apply

You bring broad technical knowledge in gene therapy and gene delivery, particularly non-viral gene delivery and have acquired deep hands-on understanding of how to develop new concepts or processes, design experiments etc. You will likely have completed a PhD in cell and gene therapy, molecular biology or biomedical engineering (or similar).

Interest in science commercialisation is a must, coupled with a strong desire to build a company to make a huge positive impact within the pharma sector.

Ideally, you will have thought about key opportunities and challenges within the CF space before and have some knowledge of pulmonary diseases and molecular genetics.

You cannot wait to get started!

About DSV

Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin out and invest in science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures.

We operate in 4 sectors: Pharmaceuticals, Energy, Agriculture and Computation, tackling the challenges defining those areas by taking a first-principles approach and partnering with leading institutions.

 

The Challenge

Cystic Fibrosis (CF) is one of the most common genetic diseases that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span. The mutational profile across CF patients is complex and while life-extending therapies exist for the most common mutations, large patient populations remain uncatered for, and curative therapies are lacking.

One of the key challenges to overcome for curative approaches to CF is delivery. CF is a systemic disease with the most life-threatening symptoms occurring in the lung, which is why the respiratory delivery route has been the focus so far. However, to tackle all affected tissues, we will need a delivery strategy to reach all affected tissues whilst ensuring the therapeutic agent reaches the lung in sufficient concentrations.

 

OUR TAKE ON BUILDING NEW VENTURES IN THIS SPACE

We have teamed up with the Cystic Fibrosis Foundation (CFF), the world’s leading organisation with the mission to cure CF and to provide all people with CF the opportunity to lead long, fulfilling lives. Together we will focus on developing lifesaving new therapies for larger numbers of people with CF – including those with rare and nonsense mutations – and pursuing daring, new opportunities to one day develop a lifelong cure that targets the disease from every angle. You will be applying DSV’s approach to ideation and venture building whilst tapping into CFF’s network and expertise, including technical, non-clinical and regs throughout the process.

 

The Opportunity for you

Joining DSV is a fantastic opportunity to develop concepts for and launch your own therapeutics startup.

Taking up a Founding Analyst (FA) role at DSV differs quite significantly from the entrepreneur in residence (EIR) role in other funds or venture studios. Working with us and other founders at DSV, as well as our mentors, you’ll have access to a completely new kind of environment for creating science companies, one that does not start with university IP, but with a systematic rework of an opportunity area from first principles.

Instead of scouting for existing technologies that might overcome a specific challenge, an FA starts with identifying the areas where there is neglect or repeated failure yet potential solutions exist if considered from a different perspective, mapping the limitations to existing approaches at the specific and macro-level and considering the constraints of the broader ecosystem (capital, expertise, IP, knowledge, competition).

Within less than 12 months you will have developed a few promising concepts, built a team of multidisciplinary co-founders and experienced advisors, incorporated a new company and spun-out of DSV to start the early tech development / proof-of-concept work with investment secured from DSV and CFF.

 

Our offer

We provide a monthly salary (at a pre-seed stage startup level) to bridge the gap between developing your new venture and getting it to an investable company stage. CFF will bring deep expertise in the space, apply time from their own staff to assist with the venture development process and DSV will support you with building a founding team and securing investors. You and your Co-Founder(s) will own 80% of the new venture at inception and the pre-seed investment capital is already secured from CFF.

 

Our impact

We’ve so far built and invested in 9 brand new companies in the pharma in the curative therapeutics sector including in neurodegeneration, oncology and infectious diseases.

You can read some our Founder stories here.

 

Who should apply

You bring broad technical knowledge in gene therapy and gene delivery, particularly non-viral gene delivery and have acquired deep hands-on understanding of how to develop new concepts or processes, design experiments etc. You will likely have completed a PhD in cell and gene therapy, molecular biology or biomedical engineering (or similar).

Interest in science commercialisation is a must, coupled with a strong desire to build a company to make a huge positive impact within the pharma sector.

Ideally, you will have thought about key opportunities and challenges within the CF space before and have some knowledge of pulmonary diseases and molecular genetics.

You cannot wait to get started!

Interviews ongoing for a full-time start in asap

Interviews ongoing for a full-time start in asap